Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years
Lusine Kostanyan, Iris Wu, Melissa Sinkiewicz, Jose Cardona, Kimball Johnson, Rituparna Das · 2026
Read Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years by Lusine Kostanyan, Iris Wu, Melissa Sinkiewicz, Jose Cardona, Kimball Johnson, Rituparna Das (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13224755.txt.
Description
Lusine Kostanyan and colleagues report a 2026 phase 3 trial update for mRNA-1083, an experimental combined vaccine against seasonal flu and COVID-19 in one shot. Adults aged fifty and older were randomly assigned to the combined product or to standard licensed vaccines for each disease. Earlier results covered the first month; the new report extends follow-up to six months.
Antibody responses against all matched flu strains held up through six months and matched or beat the standard vaccines. Responses against the coronavirus stayed higher in the combined-vaccine group throughout. Side effects were mostly mild to moderate, and no vaccine-related serious events or deaths occurred, supporting the single-shot approach for older adults.
Catalog record
| CREATOR | Lusine Kostanyan, Iris Wu, Melissa Sinkiewicz, Jose Cardona, Kimball Johnson, Rituparna Das |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |